This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
The purpose of this study is to compare the efficacy of zipalertinib versus placebo in participants with early stage resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).
This study is open to adults with extensive-stage small cell lung cancer. The purpose of this study is to find out how well people with this type of cancer tolerate taking study medicines called obrixtamig and pumitamig. Another purpose is to check whether the combination study treatment can make tumours shrink. Obrixtamig and pumitamig are being developed to help the immune system fight cancer. Participants are put into 2 groups. One group gets obrixtamig and pumitamig. The other group gets obrixtamig and pumitamig with standard chemotherapy (carboplatin and etoposide). All study treatments are given as infusions into a vein. This study does not have a fixed duration. Participants can receive obrixtamig and pumitamig for up to 2 years if they benefit from treatment and can tolerate it. Participants visit the study site regularly, with some overnight stays required. During this time, doctors regularly check for health problems that could be caused by the study treatment. They also monitor the size of the tumour(s) and take laboratory tests.
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer.
The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy or in combination with Izalontamab Brengitecan in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion or MTAP loss after progression on prior therapies.
The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by measuring the number of people with a certain number of living cancer cells in the tumor removed during surgery.
Original English text from ClinicalTrials.gov
✓ Qualifies
✗ Disqualifies
Simplified criteria — AI translation
Southern Cancer Center (SCC) ( Site 8004)
Daphne, United States
Sansum Clinic (Ridley Tree) ( Site 8012)
Santa Barbara, United States
Rocky Mountain Cancer Centers (RMCC) ( Site 8011)
Lone Tree, United States
Greenebaum Comprehensive Cancer Center ( Site 0402)
Baltimore, United States
MedStar Franklin Square Medical Center ( Site 0033)
Baltimore, United States
Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8006)
Eugene, United States
Texas Oncology - Central/South Texas ( Site 8009)
Austin, United States
Texas Oncology - Northeast Texas ( Site 8005)
Tyler, United States
Virginia Cancer Specialists (VCS) ( Site 8002)
Fairfax, United States
Centro de Estudios Clínicos SAGA ( Site 0162)
Santiago, Chile
FALP ( Site 0161)
Santiago, Chile
Bradfordhill ( Site 0160)
Santiago, Chile
Alexandra General Hospital of Athens Oncology-Hematology Unit ( Site 0203)
Athens, Greece
ATTIKON GENERAL UNIVERSITY HOSPITAL-Oncology ( Site 0202)
Athens, Greece
Metropolitan Hospital-4th Oncology Dept ( Site 0201)
Athens, Greece
University General Hospital of Heraklion ( Site 0200)
Heraklion, Greece
Petz Aladar Egyetemi Oktato Korhaz-Pulmonológia (Dr. Szalai Zsuzsanna) ( Site 0062)
Győr, Hungary
Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 0061)
Szolnok, Hungary
Országos Korányi Pulmonológiai Intézet ( Site 0060)
Budapest, Hungary
Azienda Ospedaliera Universitaria Careggi ( Site 0173)
Florence, Italy
Ospedale San Raffaele. ( Site 0171)
Milan, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0175)
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 0174)
Roma, Italy
Wielkopolskie Centrum Pulmonologii i Torakochirurgii-Oddzial Onkologii Klinicznej z Pododdzialem Dz ( Site 0153)
Poznan, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 0151)
Warsaw, Poland
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)
Gdansk, Poland
Hospital Clinic de Barcelona ( Site 0092)
Barcelona, Spain
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 0702)
Adana, Turkey (Türkiye)
Hacettepe Universite Hastaneleri-oncology hospital ( Site 0700)
Ankara, Turkey (Türkiye)
Akdeniz Universitesi Hastanesi-Medical Oncology ( Site 0704)
Antalya, Turkey (Türkiye)
İzmir Suat Seren Chest Disease Training & Research Hospital ( Site 0701)
Izmir, Turkey (Türkiye)
Ondokuz Mayıs Universitesi-Oncology department ( Site 0706)
Samsun, Turkey (Türkiye)
CNE CC of Oncology Hematol ( Site 0130)
Cherkasy, Ukraine
Municipal Enterprise "Bukovinian сlinical oncology сenter" ( Site 0139)
Chernivtsi, Ukraine
CNCE Precarpathian Clinical Oncologic Center ( Site 0131)
Ivano-Frankivsk, Ukraine
MNPE LTMU Multidisc. Clin. Hosp. of Emerg. and Intens. Care ( Site 0132)
Lviv, Ukraine
ME RIVNE REGIONAL ANTITUMOR CENTER ( Site 0460)
Rivne, Ukraine
Communal Noncommercial Enterprise "Podillia Regional Oncology Center Of Vinnytsia Regional Council" ( Site 0135)
Vinnytsia, Ukraine
Shalimov Institute of Surgery and Transplantation ( Site 0138)
Kyiv, Ukraine
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/2/2026.
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.
We use Google Analytics to understand how you use our tools and to improve them. We don't collect health data and we don't show ads. You can decline - the site will work exactly the same. Privacy policy